Last reviewed · How we verify
NNC0365-3769 (Mim8) PPX
Mim8 PPX is a glucagon-like peptide-1 (GLP-1) receptor agonist.
Mim8 PPX is a glucagon-like peptide-1 (GLP-1) receptor agonist. Used for Type 2 diabetes.
At a glance
| Generic name | NNC0365-3769 (Mim8) PPX |
|---|---|
| Sponsor | Novo Nordisk A/S |
| Drug class | GLP-1 receptor agonist |
| Target | GLP-1R |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Mim8 PPX works by binding to and activating the GLP-1 receptor, which increases glucose-dependent insulin secretion, decreases glucagon secretion, and slows gastric emptying.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Vomiting
- Diarrhea
Key clinical trials
- A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors (PHASE3)
- A Research Study Looking at How Safe it is to Switch From Emicizumab to Mim8 in People With Haemophilia A (FRONTIER 5) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NNC0365-3769 (Mim8) PPX CI brief — competitive landscape report
- NNC0365-3769 (Mim8) PPX updates RSS · CI watch RSS
- Novo Nordisk A/S portfolio CI